Aspira Pathlab & Diagnostics
- Market cap
- ₹ 131 Cr.
- P/E
- 53.9x
- P/B
- 10.39x
- 52-week range
- 49 – 149.99
- ROE
- 1%
- ROCE
- 2.8%
- Dividend yield
- 0%
- Debt / equity
- 0.27
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE
About
Aspira Pathlab & Diagnostics Limited is an India-based company, which is engaged in the business of running, owning, managing, and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at diagnostic centers in Mumbai. The Company carries out pathological investigations in various branches, including biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company's tests include pathology test, sonography, x-ray, and radiology. Its pathology tests include Influenza (Flu) Panel with H3N2, Blood chromosome analysis, Filmarray multiplex PCR(BIOFIRE) Pneumonia Panel Plus, Polycystic Ovarian Syndrome (PCOS) 2, Typhoid PCR, Dengue-Chikungunya-Malaria multiplex PCR, Vitamin And TSH, Fever screening profile-2, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Aspira Pathlab & Diagnostics against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)53.9 against a typical 21: pricier than most peers (1st = cheapest).25th of 34
- Sales growth+17.5% against a typical +19.1% from a year earlier.18th of 31
- Profit growth−108.5% against a typical +25.2% from a year earlier.23rd of 24
- Share price, 3 months+12.7% against a typical −7.7%.5th of 33
- Size₹ 131.4 Cr. market value against a typical ₹ 83 Cr. (1st = largest).15th of 34
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 3 | 4 | 5 | 6 | 5 | 6 | 5 | 8 | 5 | 7 | 6 |
| Expenses | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 4 | 6 | 6 | 7 | 6 |
| Operating Profit | −0 | −0 | −0 | 0 | 1 | 1 | 1 | 1 | 2 | −1 | −0 | 0 |
| OPM % | −10.8% | −10.7% | −3.4% | 7.5% | 21.8% | 14.1% | 18.2% | 15.4% | 27.1% | −23.6% | −5.1% | 5.5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −1 | −1 | −1 | −0 | 1 | 0 | 1 | 0 | 2 | −2 | −1 | −0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −1 | −1 | −1 | −0 | 1 | 0 | 1 | 0 | 2 | −2 | −1 | −0 |
| EPS in Rs | −0.69 | −0.72 | −0.49 | −0.02 | 0.96 | 0.37 | 0.7 | 0.46 | 1.79 | −1.52 | −0.67 | −0.04 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 10%
- 3 Years
- 20%
- TTM
- 15%
- 10 Years
- 5%
- 5 Years
- −49%
- 3 Years
- 37%
- TTM
- −118%
- 10 Years
- —
- 5 Years
- 19%
- 3 Years
- 50%
- TTM
- —
- 10 Years
- —
- 5 Years
- 11%
- 3 Years
- −2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Aspira Pathlab & Diagnostics | ₹ 128.00 | ₹ 131 Cr. | 53.9x | 10.4x | 1% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.1x | 13.3x | — | 8.1% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 65.4x | 9x | — | 16.7% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 65.4x | 7x | — | 11.3% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 95.8x | 8.7x | — | 7.4% |
| Global Health | ₹ 1,165.00 | ₹ 31,449 Cr. | 68.1x | 9.6x | — | 11.8% |
Prices are delayed and for information only. Nothing on this page is investment advice.